OREANDA-NEWS. Ergomed plc, announces that, following its recent acquisitions of Dr. Oestreich + Partner GmbH ('O+P') and Gesellschaft f?r angewandte Statistik + Datenanalyse mbH ('GASD') in Germany, it has signed its first contract with an existing O+P and GASD customer to provide a significantly broader suite of services from the entire Group.  The long-standing customer will be using O+P's proprietary electronic data capture system, OPVERDI.

At the time of the acquisitions, it was noted that O+P and GASD enjoy strong brand awareness in their home markets and that a key rationale for the deals was the potential for cross-selling across offerings available within the broader Ergomed business, providing a "one-stop shop" for clinical trial service needs.  This €1.5 million contract covers six countries and supports Ergomed's broader approach to seek bolt-on acquisitions that further expand and enhance the menu of clinical trial services offered by the Group.

Commenting on the news Dr. Miroslav Reljanovic, Chief Executive Officer of Ergomed, said: "I am delighted to announce this contract win with an existing customer of O+P and GASD.  The significantly broadened suite of Ergomed services provided to this customer validates the rationale behind our recent acquisitions of these German businesses.  Offering a comprehensive range of clinical trial solutions will enable us to grow our existing business as well as attract customers from new markets.  As such, we will continue to seek bolt-on acquisitions that enhance our menu of Services and position Ergomed as a one-stop shop for all our customer's clinical trial service needs."

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.